http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10183036-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_015145cfcc4ffcf7427d01ebf7f8345a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-04 |
| filingDate | 2017-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ad08d2d65bcc4a764835ed14c1ac84a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_033cd6749dfe367c5425bad03bcaa407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ccb3bacc9d20f29c542d045c544f7ea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7ea1b87b36dc641ca2407905e884893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50d017b757a716167633af0dbaa9cad9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d00d4d492743dbd7f7ca67a87d654f76 |
| publicationDate | 2019-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-10183036-B2 |
| titleOfInvention | Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors |
| abstract | Compositions are provided including nicotinic acid riboside (“NAR”), and derivatives thereof including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-nicotinic acid (“NAR triacetate” or “NARTA”); or derivatives of a reduced form of nicotinic acid riboside (“NARH”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (“NARH triacetate” or “NARH-TA”); or derivatives of nicotinamide riboside (“NR”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-nicotinamide (“NR triacetate” or “NRTA”); derivatives of a reduced form of nicotinamide riboside (“NRH”), including 1-(2′,3′,5′-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinamide (“NRH triacetate” or “NRH-TA”); or salts or prodrugs thereof, for use in food or beverage applications, pharmaceutical formulations, or as a dietary supplement. Methods of using the compounds above to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (“NAD+”) or NADH in cells and tissues for improving cell and tissue survival or overall cell and tissue health are provided. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11098076-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10392414-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023150072-A1 |
| priorityDate | 2016-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 619.